​

Vivos Therapeutics, Inc.

NasdaqCM:VVOS Stock Report

Market Cap: US$30.4m

Vivos Therapeutics (VVOS) Stock Overview

Operates as a medical technology company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. More details

VVOS fundamental analysis
Snowflake Score
Valuation0/6
Future Growth1/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Rewards

Revenue is forecast to grow 16.77% per year

Earnings have grown 3.6% per year over the past 5 years

Risk Analysis

Has less than 1 year of cash runway

Shareholders have been substantially diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years

Does not have a meaningful market cap ($30M)

+ 1 more risk

VVOS Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

INBS logo
Intelligent Bio Solutions
JO
Jolt_Communications
Community Contributor

The Future of Drug Testing? Fingerprint Tech Shows Serious Promise

Key Takeaways Intelligent Bio Solutions has a new way to test for drugs using fingerprints: it’s quick, portable, and doesn’t require pee cups or saliva swabs. With commercial traction in 24 countries and over 450 active accounts, INBS is now targeting the U.S. market, where over 55 million drug tests are performed annually.
View narrative
US$2.98
FV
42.6% undervalued intrinsic discount
59.20%
Revenue growth p.a.
10users have liked this narrative
0users have commented on this narrative
57users have followed this narrative
about 1 month ago author updated this narrative
VVOS logo
Vivos Therapeutics
AN
AnalystConsensusTarget
Consensus Narrative from 2 Analysts

Acquisitions And Sleep Center Integrations Will Expand Future Markets

Key Takeaways Pivoting from dentist-led distribution to integrating with sleep medicine providers should boost margins, revenue growth, and capture more value from the sleep apnea market. Recent acquisitions and new business model aim for profitability, reduced cash burn, and capitalize on industry consolidation through a scalable expansion strategy.
View narrative
US$4.23
FV
21.2% overvalued intrinsic discount
12.50%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
6 days ago author updated this narrative
View Vivos Therapeutics Community

Vivos Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Vivos Therapeutics
Historical stock prices
Current Share PriceUS$5.12
52 Week HighUS$6.28
52 Week LowUS$1.97
Beta6.98
1 Month Change129.60%
3 Month Change106.45%
1 Year Change111.13%
3 Year Change-86.26%
5 Year Changen/a
Change since IPO-97.72%

Recent News & Updates

Vivos Therapeutics, Inc. (NASDAQ:VVOS) Stock Rockets 60% As Investors Are Less Pessimistic Than Expected

Jul 02
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Stock Rockets 60% As Investors Are Less Pessimistic Than Expected

Recent updates

Vivos Therapeutics, Inc. (NASDAQ:VVOS) Stock Rockets 60% As Investors Are Less Pessimistic Than Expected

Jul 02
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Stock Rockets 60% As Investors Are Less Pessimistic Than Expected
author-image

FDA Clearance And Middle East Expansion Will Secure Future Success

Strategic alliances and clinic acquisitions aim to increase patient conversions, boosting revenue and margins through higher treatment uptake.

Positive Sentiment Still Eludes Vivos Therapeutics, Inc. (NASDAQ:VVOS) Following 26% Share Price Slump

Apr 05
Positive Sentiment Still Eludes Vivos Therapeutics, Inc. (NASDAQ:VVOS) Following 26% Share Price Slump

Investors Give Vivos Therapeutics, Inc. (NASDAQ:VVOS) Shares A 30% Hiding

Feb 16
Investors Give Vivos Therapeutics, Inc. (NASDAQ:VVOS) Shares A 30% Hiding

After Leaping 35% Vivos Therapeutics, Inc. (NASDAQ:VVOS) Shares Are Not Flying Under The Radar

Dec 27
After Leaping 35% Vivos Therapeutics, Inc. (NASDAQ:VVOS) Shares Are Not Flying Under The Radar

Even With A 27% Surge, Cautious Investors Are Not Rewarding Vivos Therapeutics, Inc.'s (NASDAQ:VVOS) Performance Completely

Nov 12
Even With A 27% Surge, Cautious Investors Are Not Rewarding Vivos Therapeutics, Inc.'s (NASDAQ:VVOS) Performance Completely

Vivos Therapeutics, Inc.'s (NASDAQ:VVOS) Shares Leap 41% Yet They're Still Not Telling The Full Story

Sep 10
Vivos Therapeutics, Inc.'s (NASDAQ:VVOS) Shares Leap 41% Yet They're Still Not Telling The Full Story

It's Down 44% But Vivos Therapeutics, Inc. (NASDAQ:VVOS) Could Be Riskier Than It Looks

Apr 25
It's Down 44% But Vivos Therapeutics, Inc. (NASDAQ:VVOS) Could Be Riskier Than It Looks

It's Down 48% But Vivos Therapeutics, Inc. (NASDAQ:VVOS) Could Be Riskier Than It Looks

Feb 02
It's Down 48% But Vivos Therapeutics, Inc. (NASDAQ:VVOS) Could Be Riskier Than It Looks

Fewer Investors Than Expected Jumping On Vivos Therapeutics, Inc. (NASDAQ:VVOS)

Apr 18
Fewer Investors Than Expected Jumping On Vivos Therapeutics, Inc. (NASDAQ:VVOS)

Vivos Therapeutics again delays Q2 2022 results

Aug 23

Vivos Therapeutics signs exclusive distribution agreement with GM Instruments for US and Canada

Jun 29

Shareholder Returns

VVOSUS HealthcareUS Market
7D32.3%-6.4%0.4%
1Y111.1%-19.2%12.6%

Return vs Industry: VVOS exceeded the US Healthcare industry which returned -19.5% over the past year.

Return vs Market: VVOS exceeded the US Market which returned 12.5% over the past year.

Price Volatility

Is VVOS's price volatile compared to industry and market?
VVOS volatility
VVOS Average Weekly Movement15.3%
Healthcare Industry Average Movement7.0%
Market Average Movement7.1%
10% most volatile stocks in US Market17.3%
10% least volatile stocks in US Market3.7%

Stable Share Price: VVOS's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: VVOS's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2016113R. Huntsmanwww.vivos.com

Vivos Therapeutics, Inc. operates as a medical technology company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children.

Vivos Therapeutics, Inc. Fundamentals Summary

How do Vivos Therapeutics's earnings and revenue compare to its market cap?
VVOS fundamental statistics
Market capUS$30.45m
Earnings (TTM)-US$11.24m
Revenue (TTM)US$14.63m
2.1x
P/S Ratio
-2.7x
P/E Ratio

Is VVOS overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
VVOS income statement (TTM)
RevenueUS$14.63m
Cost of RevenueUS$6.04m
Gross ProfitUS$8.59m
Other ExpensesUS$19.83m
Earnings-US$11.24m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-1.91
Gross Margin58.73%
Net Profit Margin-76.82%
Debt/Equity Ratio0%

How did VVOS perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/08 06:35
End of Day Share Price 2025/07/08 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Vivos Therapeutics, Inc. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Scott HenryAlliance Global Partners
Lucas WardAscendiant Capital Markets LLC
Alexander NowakCraig-Hallum Capital Group LLC